Streetwise Expert Interviews

Douglas Loe

Doug Loe: Canada Has Earned Its Spot in the Biotech All-Star Team Photo

Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences Report, Loe gives the Canadian life sciences industry an upbeat prognosis, and offers ideas on companies that could realize generous returns in the sector in 2015.

(12/18/14) More >

2015 Small-Cap Biotech Watchlist Announced

In its third year, The Life Sciences Report's 2015 Small-Cap Biotech Watchlist currently includes 12 drug development companies selected by leading analysts in the sector. With catalysts on the horizon and pipelines that encompass a variety of indications and innovative platforms, these biotechs are primed to return multiples on investment.

(12/18/14) More >
Read More Streetwise Interviews

Wedbush Securities' David Nierengarten on Genetic Cures for Disease: Impossible Dream Come True?

David Nierengarten of Wedbush Securities explores gene therapies that actually correct an inborn mutation in human DNA, creating permanent change, actual cures, better lives for patients. . .and the opportunity for investors to capture serious returns on risk capital. (12/11/14) More >

Newsletter Briefs

"RNN has decent short-term momentum and is seeing solid activity on the earnings estimate revision front." (12/10/14) Rexahn Pharmaceuticals Inc. - Zacks Equity Research More >

"Analysts are becoming more bullish on INO's prospects in both the short and long term." (12/5/14) Inovio Pharmaceuticals Inc. - Zacks Equity Research More >

"There is extraordinary upside potential in STEM." (12/4/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James More >

"You have lots of shots on goal with RNN." (12/4/14) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Christopher James More >

"MSLP has definitely proven itself a very capable marketing machine." (11/20/14) MusclePharm Corp. - The Life Sciences Report Interview with Dick Huebner More >

"OMER's Omidria is FDA-approved, proven sterile and safe, and reimbursable by payers." (11/13/14) Omeros Corp. - The Life Sciences Report Interview with Steve Brozak More >

"GLPG is notable and underappreciated." (11/12/14) Galapagos NV - The Life Sciences Report Interview with George Zavoico More >

"NBS will announce results from its Phase 2b PreSERVE-AMI trial on Nov. 17." (11/13/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >

Expert Analysis

"We believe CGIX's revenues will continue to grow in coming quarters." (12/5/14) Cancer Genetics Inc. - Yi Chen, Aegis Capital More >

"THLD presented data from Part C of its Phase 1/2 TH-302 study in MM." (12/8/14) Threshold Pharmaceuticals Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"ATHX is positioning itself to grab a Japanese revenue opportunity that would place an entirely new valuation on the company." (11/26/14) Athersys Inc. - Wall Street Titan, Seeking Alpha More >

"NBS as a window to be first cell therapy to the marketplace." (12/2/14) NeoStem Inc. - Jason Kolbert, Maxim Group More >

"ATHX is well positioned in terms of its stage of development and the profile of its MAPCs." (11/24/14) Athersys Inc. - Christian Glennie, Edison Investment Research More >

"Phase 3 trials for MSB's MPV-06-ID in back pain should start by 2014E." (11/24/14) Mesoblast Ltd. - Katherine Genis, Edison Investment Research More >

"NBS' cardiac data are encouraging." (11/24/14) NeoStem Inc. - Jason Kolbert, Maxim Group More >

"INO is going after melanoma with a new, novel approach." (11/20/14) Inovio Pharmaceuticals Inc. - Jason Kolbert, Maxim Group More >